Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2015

01.09.2015 | short review

ASH 2014 update: Myelodysplastic syndromes and acute myeloid leukemia

verfasst von: MBA Univ.-Prof. Dr. Michael Pfeilstöcker

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), especially in older patients with comorbidities, is still a challenge and awaits further improvement regarding outcomes. Therefore data presented on this topic at the 2014 American Society of Hematology (ASH) meeting are of importance and need to be discussed in the context of current and future clinical practice. This review covers studies for AML and MDS (excluding transplantation) reported at the last ASH meeting that demonstrate progress in this field and suggest a way forward from chemotherapy to biological treatment approaches.
Literatur
1.
Zurück zum Zitat Fink EM, Krönke J, Hurst SN, et al. Lenalidomide Induces Ubiquitination and Degradation of CSNK1A1 in MDS with Del(5q). Blood. 2014;124. (abstr 4) Fink EM, Krönke J, Hurst SN, et al. Lenalidomide Induces Ubiquitination and Degradation of CSNK1A1 in MDS with Del(5q). Blood. 2014;124. (abstr 4)
2.
Zurück zum Zitat Santini V, Almeida A, Giagounidis A, et al. Efficacy and safety of lenalidomide (LEN) versus placebo (PBO) in RBC-transfusion dependent (TD) patients (Pts) with IPSS low/intermediate (Int-1)-risk myelodysplastic syndromes (MDS) without Del(5q) and unresponsive or refractory to erythropoiesis-stimulating agents (ESAs): results from a randomized phase 3 study (CC-5013-MDS-005). Blood. 2014;124. (abstr 409). Santini V, Almeida A, Giagounidis A, et al. Efficacy and safety of lenalidomide (LEN) versus placebo (PBO) in RBC-transfusion dependent (TD) patients (Pts) with IPSS low/intermediate (Int-1)-risk myelodysplastic syndromes (MDS) without Del(5q) and unresponsive or refractory to erythropoiesis-stimulating agents (ESAs): results from a randomized phase 3 study (CC-5013-MDS-005). Blood. 2014;124. (abstr 409).
3.
Zurück zum Zitat Komrokji RS, Garcia-Manero G, Ades L, et al. An open-label, phase 2, dose-finding study of sotatercept (ACE-011) in patients with low or intermediate-1 (Int-1) -risk myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML) and anemia requiring transfusion. Blood. 2014;124. (abstr 3251). Komrokji RS, Garcia-Manero G, Ades L, et al. An open-label, phase 2, dose-finding study of sotatercept (ACE-011) in patients with low or intermediate-1 (Int-1) -risk myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML) and anemia requiring transfusion. Blood. 2014;124. (abstr 3251).
4.
Zurück zum Zitat Platzbecker U, Germing U, Giagounidis A, et al. ACE-536 increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): preliminary results from a phase 2 study. Blood. 2014;124. (abstr 411). Platzbecker U, Germing U, Giagounidis A, et al. ACE-536 increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): preliminary results from a phase 2 study. Blood. 2014;124. (abstr 411).
5.
Zurück zum Zitat Silverman LR, Greenberg P, Raza A, et al. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol. 2014. doi:10.1002/hon.2137. Silverman LR, Greenberg P, Raza A, et al. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol. 2014. doi:10.1002/hon.2137.
6.
Zurück zum Zitat Garcia-Manero G, Fenaux P, Al-Kali A, et al. Overall survival and subgroup analysis from a randomized phase III study of intravenous rigosertib versus best supportive care (BSC) in patients (pts) with higher-risk myelodysplastic syndrome (HR-MDS) after failure of hypomethylating agents (HMAs). Blood. 2014;124. (abstr 163). Garcia-Manero G, Fenaux P, Al-Kali A, et al. Overall survival and subgroup analysis from a randomized phase III study of intravenous rigosertib versus best supportive care (BSC) in patients (pts) with higher-risk myelodysplastic syndrome (HR-MDS) after failure of hypomethylating agents (HMAs). Blood. 2014;124. (abstr 163).
7.
Zurück zum Zitat Sekeres MA, Othus M, List AF, et al. A randomized phase II study of azacitidine combined with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML): north American intergroup study SWOG S1117. Blood. 2014;124. (Late breaking abstr 5). Sekeres MA, Othus M, List AF, et al. A randomized phase II study of azacitidine combined with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML): north American intergroup study SWOG S1117. Blood. 2014;124. (Late breaking abstr 5).
8.
Zurück zum Zitat Röllig C, Müller-Tidow C, Hüttmann A, et al. Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: results from 267 patients treated in the randomized placebo-controlled SAL-Soraml trial. Blood. 2014;124. (abstr 6). Röllig C, Müller-Tidow C, Hüttmann A, et al. Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: results from 267 patients treated in the randomized placebo-controlled SAL-Soraml trial. Blood. 2014;124. (abstr 6).
9.
Zurück zum Zitat Stein EM, Altman JK, Collins R, et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies. Blood. 2014; 124. (abstr 115). Stein EM, Altman JK, Collins R, et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies. Blood. 2014; 124. (abstr 115).
10.
Zurück zum Zitat Ravandi F, Ritchie E, Sayar H, et al. Improved survival in patients with first relapsed or refractory acute myeloid leukemia (AML) treated with vosaroxin plus cytarabine versus placebo plus cytarabine: results of a phase 3 double-blind randomized controlled multinational study (VALOR). Blood. 2014;124. (Late breaking abstr 6). Ravandi F, Ritchie E, Sayar H, et al. Improved survival in patients with first relapsed or refractory acute myeloid leukemia (AML) treated with vosaroxin plus cytarabine versus placebo plus cytarabine: results of a phase 3 double-blind randomized controlled multinational study (VALOR). Blood. 2014;124. (Late breaking abstr 6).
11.
Zurück zum Zitat Castaigne S, Pautas C, Terré C, et al. Final analysis of the ALFA 0701. Study Blood. 2014;124. (abstr 376). Castaigne S, Pautas C, Terré C, et al. Final analysis of the ALFA 0701. Study Blood. 2014;124. (abstr 376).
12.
Zurück zum Zitat Amadori S, Suciu S, Selleslag D, et al. Improved overall survival with gemtuzumab ozogamicin (GO) compared with best supportive care (BSC) in elderly patients with untreated acute myeloid leukemia (AML) not considered fit for intensive chemotherapy: final results from the randomized phase III study (AML-19) of the EORTC and Gimema Leukemia Groups. Blood. 2014;124. (abstr 619). Amadori S, Suciu S, Selleslag D, et al. Improved overall survival with gemtuzumab ozogamicin (GO) compared with best supportive care (BSC) in elderly patients with untreated acute myeloid leukemia (AML) not considered fit for intensive chemotherapy: final results from the randomized phase III study (AML-19) of the EORTC and Gimema Leukemia Groups. Blood. 2014;124. (abstr 619).
13.
Zurück zum Zitat Platzbecker U, Avvisati G, Ehninger G, et al. Improved outcome with ATRA-arsenic trioxide compared to ATRA-chemotherapy in non-high risk acute promyelocytic leukemia—updated results of the Italian-German APL0406 trial on the extended final series. Blood. 2014;124. (abstr 12). Platzbecker U, Avvisati G, Ehninger G, et al. Improved outcome with ATRA-arsenic trioxide compared to ATRA-chemotherapy in non-high risk acute promyelocytic leukemia—updated results of the Italian-German APL0406 trial on the extended final series. Blood. 2014;124. (abstr 12).
14.
Zurück zum Zitat Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–32. PubMedCentralCrossRefPubMed Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–32. PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–9. CrossRefPubMed Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–9. CrossRefPubMed
16.
Zurück zum Zitat Dombret H, Seymour JF, Butrym A, et al. Results of a phase 3, multicenter, randomized, open-label study of azacitidine vs conventional care regimens in older patients with newly diagnosed acute myeloid leukemia. Haematologica 2014;99(s1):788–9. (EHA 2014, Late breaking abstr LB2433). Dombret H, Seymour JF, Butrym A, et al. Results of a phase 3, multicenter, randomized, open-label study of azacitidine vs conventional care regimens in older patients with newly diagnosed acute myeloid leukemia. Haematologica 2014;99(s1):788–9. (EHA 2014, Late breaking abstr LB2433).
17.
Zurück zum Zitat Seymour JF, Döhner H, Butrym A, et al. Azacitidine (AZA) versus conventional care regimens (CCR) in older patients with newly diagnosed acute myeloid leukemia (>30% bone marrow blasts) with myelodysplasia-related changes: a subgroup analysis of the AZA-AML-001. Blood. 2014;124. (abstr 10). Seymour JF, Döhner H, Butrym A, et al. Azacitidine (AZA) versus conventional care regimens (CCR) in older patients with newly diagnosed acute myeloid leukemia (>30% bone marrow blasts) with myelodysplasia-related changes: a subgroup analysis of the AZA-AML-001. Blood. 2014;124. (abstr 10).
18.
Zurück zum Zitat Döhner H, Seymour JF, Butrym A, et al. Overall survival in older patients with newly diagnosed acute myeloid leukemia (AML) with >30% bone marrow blasts treated with azacitidine by cytogenetic risk status: results of the AZA-AML-001 study. Blood. 2014;124. (abstr 621). Döhner H, Seymour JF, Butrym A, et al. Overall survival in older patients with newly diagnosed acute myeloid leukemia (AML) with >30% bone marrow blasts treated with azacitidine by cytogenetic risk status: results of the AZA-AML-001 study. Blood. 2014;124. (abstr 621).
19.
Zurück zum Zitat Pleyer L, Burgstaller S, Stauder R, et al. Azacitidine in acute myeloid leukemia: comparison of patients with AML-MRF vs AML-NOS enrolled in the Austrian azacitidine registry. Blood. 2014;124. (abstr 3681). Pleyer L, Burgstaller S, Stauder R, et al. Azacitidine in acute myeloid leukemia: comparison of patients with AML-MRF vs AML-NOS enrolled in the Austrian azacitidine registry. Blood. 2014;124. (abstr 3681).
20.
Zurück zum Zitat Pleyer L, Burgstaller S, Stauder R, et al. Azacitidine in patients with acute myeloid leukemia: impact of intermediate-risk vs high-risk cytogenetics on patient outcomes. Blood. 2014;124. (abstr 955). Pleyer L, Burgstaller S, Stauder R, et al. Azacitidine in patients with acute myeloid leukemia: impact of intermediate-risk vs high-risk cytogenetics on patient outcomes. Blood. 2014;124. (abstr 955).
21.
Zurück zum Zitat Al-Ali HF, Krahl R, Cross M, et al. Response-adapted sequential azacitidine and induction chemotherapy in patients >60 years old with newly diagnosed AML eligible for chemotherapy (RAS-AZIC): results of the phase I of the DRKS00004519 study. Blood. 2014;124. (abstr 2310). Al-Ali HF, Krahl R, Cross M, et al. Response-adapted sequential azacitidine and induction chemotherapy in patients >60 years old with newly diagnosed AML eligible for chemotherapy (RAS-AZIC): results of the phase I of the DRKS00004519 study. Blood. 2014;124. (abstr 2310).
22.
Zurück zum Zitat Oliva EN, Alati C, Salutari P, et al. Azacitidine as post-remission therapy in elderly patients with acute myeloid leukemia significantly prolongs disease-free survival: interim results from a prospective, randomized, open-label, phase III multicenter trial. Blood. 2014;124. (abstr 2299). Oliva EN, Alati C, Salutari P, et al. Azacitidine as post-remission therapy in elderly patients with acute myeloid leukemia significantly prolongs disease-free survival: interim results from a prospective, randomized, open-label, phase III multicenter trial. Blood. 2014;124. (abstr 2299).
23.
Zurück zum Zitat Wei A, Lewis ID, Hahn U, et al. Maintenance lenalidomide for adults aged 18–65 years with AML in first complete remission after intensive chemotherapy: a phase Ib dose-escalation study of the Australasian Leukemia and Lymphoma Group (ALLG). Blood. 2014;124. (abstr 944). Wei A, Lewis ID, Hahn U, et al. Maintenance lenalidomide for adults aged 18–65 years with AML in first complete remission after intensive chemotherapy: a phase Ib dose-escalation study of the Australasian Leukemia and Lymphoma Group (ALLG). Blood. 2014;124. (abstr 944).
25.
Zurück zum Zitat Wang ES. Treating acute myeloid leukemia in older adults. Hematology. 2014;2014:14–20. (ASH educational book) CrossRefPubMed Wang ES. Treating acute myeloid leukemia in older adults. Hematology. 2014;2014:14–20. (ASH educational book) CrossRefPubMed
Metadaten
Titel
ASH 2014 update: Myelodysplastic syndromes and acute myeloid leukemia
verfasst von
MBA Univ.-Prof. Dr. Michael Pfeilstöcker
Publikationsdatum
01.09.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0219-3

Weitere Artikel der Ausgabe 3/2015

memo - Magazine of European Medical Oncology 3/2015 Zur Ausgabe